Study links feline obesity to microbiome shifts, tests FMT

A new feline obesity study is pushing the conversation beyond body condition score alone. In an April 2026 paper in Veterinary Sciences, investigators used a multi-omics approach to compare gut microbiota and serum metabolites across cats with different body conditions, then tested whether fecal microbiota transplantation could reshape those patterns. Their main finding: FMT changed the microbiome in the direction of the donor, but not enough, at least over the study period, to move body weight or routine serum biochemistry. (researchgate.net)

That fits with where the field is heading. A recent review in Frontiers in Veterinary Science describes feline obesity as the most common nutritional disorder in domestic cats, with reported prevalence ranging from 11.5% to 63%, and emphasizes that the condition is driven by a mix of genetic, hormonal, environmental, and behavioral factors. The same review argues that the field is shifting toward metabolic health and earlier risk detection, not just reactive weight-loss plans after obesity is established. (frontiersin.org)

In the new study, the authors evaluated 24 cats classified as obese, normal, or lean, then ran a second experiment in which fecal microbiota from obese or lean donors was transplanted into recipient cats. They found no significant differences in overall microbial diversity or community structure between body-condition groups, but they did identify taxonomic differences, including enrichment of Coriobacteriaceae and Collinsella in obese cats and greater abundance of Enterobacteriaceae-related taxa in normal-weight cats. On the metabolomics side, the reported changes centered on amino acid and antioxidant pathways, including O-acetylcarnitine, glutathione, and tryptophan metabolism. After FMT, recipient microbial communities shifted toward donor profiles, suggesting engraftment or at least directional remodeling, but without significant short-term effects on body weight or routine serum biochemical markers. (researchgate.net)

Those results build on earlier feline microbiome work rather than overturning it. Prior studies have found that obese cats can carry distinct gut microbial signatures, and one older weight-loss study suggested that a standardized weight-loss plan only minimally changed the fecal bacterial microbiota in obese cats. Another more recent microbiome study reported dramatic shifts in obese-cat gut communities and suggested those findings could inform future probiotic or fecal transplantation strategies. Taken together, the literature points to a real microbiome signal in feline obesity, but not yet a simple therapeutic lever. (pmc.ncbi.nlm.nih.gov)

Industry and clinical context also matter here, because FMT in cats is still early-stage medicine. A 2025 case series describing adverse events after FMT in nine cats noted that feline use remains sparsely studied, with no approved FMT product, no established indications, and limited systematic data on administration. The authors reported positive response to the presenting complaint in eight of nine cats treated for chronic diarrhea, but framed the paper specifically as a warning that clinicians should expect and track adverse events as use grows. Separate recent clinical research has also evaluated single-enema FMT in cats with chronic enteropathy, underscoring that most practical momentum for feline FMT remains in gastrointestinal disease, not obesity management. (journals.sagepub.com)

Why it matters: For veterinarians, this study is most useful as a signal-generating paper. It supports the idea that feline obesity involves microbiome-metabolome interactions that may not be captured by weight alone, which could eventually influence biomarker development, nutritional strategies, or adjunctive therapies. But it also offers a reality check: changing the microbiome is not the same as changing the patient, at least not on a clinically meaningful timeline yet. For now, the evidence still favors established obesity management tools, including individualized nutrition, monitoring, environmental change, and sustained communication with the pet parent, while microbiome-directed therapies remain investigational. (researchgate.net)

There’s also a practical caution for clinics that are curious about FMT. As interest rises, recent publications have highlighted the need for donor screening, product preparation standards, and clearer reporting around outcomes and adverse events in companion animals. That makes this new obesity paper important less as a practice-changing result and more as part of the infrastructure-building phase for microbiome therapeutics in cats. (journals.sagepub.com)

What to watch: Watch for larger controlled trials with longer follow-up, especially studies that pair FMT or other microbiome interventions with diet-based weight management, and for emerging consensus on donor selection, safety monitoring, and where feline FMT fits, if at all, outside chronic enteropathy. (researchgate.net)